Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.

By R. Azziz, E. Carmina, Didier Dewailly, E. Diamanti-Kandarakis, H. Escobar-Morreale, W. Futterweit, O. Janssen, R. Legro, R. Norman, A. Taylor and 1 more. Journal of Clinical Endocrinology and Metabolism, 2006

1,909 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/86c8357095a5930cfda0d9a6e7a64e5a5c5809a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Reproductive Medicine

Citations in the corpus

The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. (2016, background): “Most recently, the Androgen Excess and PCOS (AE-PCOS) Society (Azziz et al., 2006) recommended that clinical or biochemical hyperandrogenism should be essential for diagnosis, but also ovulatory dysfunction was required in the form of oligo-anovulation or PCO.”
Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. (2010, background): “Polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting 6–10% of reproductive-aged women (1–3) and manifested by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries in its complete phenotype (4).”
The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. (2010, positive): “This workshop suggested the addition of a third criteria—the presence of polycystic ovaries—as well as a statement that any two of the three criteria were sufﬁcient for a positive diagnosis (The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004).”
Consensus on infertility treatment related to polycystic ovary syndrome. (2008, background): “Advantages and disadvantages of these criteria, and especially the various phenotypes, were discussed in subsequent publications (Azziz et al., 2006; Franks, 2006).”
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline (2013, background): “Similarly, androgen levels decline with age in women with and without PCOS (serum T declines 50% between the ages of 20 and 40 y) (43–45), with reports of improved menstrual frequency in PCOS (46, 47), although there is little evidence to support a decline in serum T associated with the menopause tr”
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. (2009, background): “A brief summary of the Task Force’s year-long investigation and conclusions were previously published (1).”
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis (2011, background): “In 2006, the Androgen Excess–PCOS Society recommended that PCOS be defined by clinical and/or biochemical hyperandrogenism, with either oligoanovulation and/or PCO, excluding related disorders”
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. (2004, background): “Advantages and disadvantages of these criteria, and especially the various phenotypes, were discussed in subsequent publications (3, 4).”